Interactive. Enter your vial size and the dose you want per injection — it returns the exact bacteriostatic water volume to add, the concentration, and the units to draw. Includes a reference chart for common vial sizes.
Short, sourced summaries of new studies, trial results and regulatory news on GLP-1s, hormones and peptides, from the daily posts in the Dose Track community. Grouped by week.
What the FDA labels and STEP/SURMOUNT trials say about when GLP-1 side effects happen: first dose, each step-up, maintenance, with nausea rates and quit rates.
Nausea on Ozempic, Wegovy, Mounjaro and Zepbound: label rates by dose, when it happens, the fluid and kidney warning, holding a dose increase, and when to call.
About a quarter of weight lost on tirzepatide in the SURMOUNT-1 scans was lean mass, the same share as placebo. What DXA measures, STEP 1 data, and guidance on protein and strength.
In STEP 1 and SURMOUNT-1, weight curves flattened around weeks 60 to 72. How dose moves the plateau, what the labels say about maintenance doses, and why the body pushes back.
Inside the retatrutide phase 2 trials: every dose arm, weight at 24 and 48 weeks, how a 2 mg start cut nausea, heart rate, the diabetes trial, and phase 3 so far.
Every published CagriSema trial: phase 2 in diabetes, REDEFINE 1, 2 and 5, what amylin does in plain words, side effects, and where the FDA filing stands.
What 8 orforglipron trials found: -11.2% weight in ATTAIN-1, A1C wins over oral semaglutide and dapagliflozin, more side-effect stops, and how the pill differs from Rybelsus.
The rodent findings behind the GLP-1 thyroid boxed warning, the label advice on symptoms and calcitonin, and what French, Scandinavian and pooled-trial data show.
What STEP 1, STEP 4 and SURMOUNT-4 found when people stopped semaglutide or tirzepatide: weight regained within a year, blood pressure and HbA1c rising again, and clearance times.
The four GLP-1 labels are silent on drinking. Early trials of semaglutide and exenatide in alcohol use disorder had mixed results, and no GLP-1 is approved to treat it.
Mounjaro and Zepbound can make the pill less reliable. The 4-week backup rule, the study numbers, pregnancy and breastfeeding advice, and how Ozempic and Wegovy differ.
All four GLP-1 labels warn about aspiration under anesthesia. The exact wording, ASA 2023 one-week hold, the 2024 multi-society update, and what to tell your care team.
FDA reports of 5x to 20x overdoses with compounded semaglutide, the mg vs mL vs units mix-up behind them, the 2024-2025 shortage end dates, and a check before each dose.
Hair loss rates from the Wegovy and Zepbound labels by dose and by sex, what telogen effluvium is and when it starts, and when hair loss on a GLP-1 needs a doctor.
Same drug, different labels. Ozempic tops out at 2 mg, Wegovy at 2.4 mg or 7.2 mg. Dose steps, pens, missed-dose rules, approved uses and trials compared.
What to log on a GLP-1 and why: dose time, mg, site, pen open date and lot, side effects with severity, skipped doses and weight, tied to the label rules.
Every published BPC-157 study in people: three small pilots and one trial abstract. What each found, what FDA told its advisers in July 2026, and the gaps.
TB-500 is a 7-amino-acid fragment, not thymosin beta-4. What the Tβ4 eye and wound trials found, why FDA found no TB-500 human data, and its WADA status.
Plain-words guide to the 503A bulks list, FDA's categories 1, 2 and 3, the withdrawn peptide nominations, and the July 2026 advisory meeting on seven peptides.
Why a research use only or not for human consumption label does not make an injectable peptide legal, what FDA warning letters say, and what it means.
How to read a peptide certificate of analysis: HPLC purity, mass spec identity, peptide content, endotoxin, sterility, and the red flags FDA points to.
Why testosterone raises hematocrit, the Endocrine Society's 54% line and test schedule, the Xyosted label numbers, and how injection type relates to red cells.
SC vs IM testosterone: what the labels allow, and what the Xyosted trials and comparison studies found on levels, hematocrit, estradiol and pain.
Why TRT suppresses sperm, what the Endocrine Society says on fertility, the hCG co-treatment study, how long recovery takes after stopping, and the hCG label.
Enclomiphene is one of two isomers in clomiphene. What trials found on testosterone, LH, FSH and sperm, what the Clomid label says, and its 2026 FDA status.
PSA on testosterone: the Endocrine Society's 1.4 and 4.0 ng/mL referral rules, when to test, what the labels warn, and the TRAVERSE prostate safety results.
How GH secretagogues work, what human studies of CJC-1295, ipamorelin and tesamorelin found, what the Egrifta label says, and FDA and WADA status in 2026.
What NAD+ is, the only published human study of an NAD+ IV infusion, what oral precursor trials found, the FDA compounding status in 2026, and what is unknown.
SS-31 is elamipretide, approved in 2025 as Forzinity for Barth syndrome under accelerated approval. What its trials found, what failed, and the wellness gap.
How to read U-100 insulin syringe markings on 0.3, 0.5 and 1 mL barrels, units vs mL vs mg, worked examples, and why tiny volumes are harder to measure.
How many doses a vial really gives, why the discard date can end a vial before it is empty, counting syringes and water, and setting an order-by date.
A practical method for tracking several peptides at once: what to log per shot, naming vials, blends vs separate shots, one change at a time, and labs.
Tirzepatide half-life is about 5 days. What the Zepbound label says about peak time, steady state, missed doses and how long it takes to wear off after the last shot.
Saxenda clears in days, Trulicity in weeks, Wegovy in 5 to 7 weeks. Half-life, peak time and missed-dose rules for each, straight from the FDA labels.
What to log on TRT besides the shot itself: symptoms, lab timing and cycle day. Based on Endocrine Society monitoring guidance, plus how Dose Track keeps it in one place.
Head-to-head: half-life, weight loss in SURMOUNT-1 vs STEP-1 vs the SURMOUNT-5 head-to-head, side effects, dosing schedules, and 2026 cost. Cited from FDA labels and NEJM trials.
Why sensitive E2 (LC-MS/MS) is the right assay, the typical 20–40 pg/mL target, what high and low E2 actually feel like, and the cautious case for and against anastrozole on TRT.
Pentadecapeptide structure, acetate vs arginate salt forms, reconstitution math in insulin-syringe units, the real human evidence base, and the moving 2026 regulatory picture (HHS, FDA PCAC, WADA).
An honest look at low-dose semaglutide and tirzepatide — what the trial data does and doesn't say, what the pharmacology supports, and the open questions that aren't yet answered.
Lipohypertrophy, scar tissue, and absorption drift — what happens when you keep hitting the same site, and a rotation map for SC and IM injections across TRT, GLP-1, and peptides.
Why a "normal" total testosterone result can still mean low free T, how SHBG distorts the picture, and the Vermeulen calculation your lab probably isn't running for you.
Why testosterone cypionate takes 4–5 weeks to reach steady state, what your bloodwork actually shows after one shot, and how to time labs for an accurate trough.
Semaglutide has a 7-day half-life — meaning measurable plasma concentration weeks after stopping. What that means for missed doses, breaks, and switching protocols.
A clinician-grade walkthrough of the BAC water → mg/mL → insulin units math, with worked examples for BPC-157, Ipamorelin, HGH, and CJC-1295.
More guides coming. Have a topic request? hello@dosetrack.app